Should I buy Privia Health Group, Inc. (PRVA) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Privia Health Group, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Needham | 40 % | +1.6 % | 5 | $30 +44% |
| Canaccord Genuity | 50 % | -1.4 % | 8 | $34 +63% |
| Truist Securities | 43 % | -3.1 % | 7 | $33 +58% |
| JP Morgan | 40 % | -3.7 % | 5 | $33 +58% |
| SVB Leerink | 43 % | -1.1 % | 7 | — |
| Credit Suisse | 14 % | -24.6 % | 7 | — |
✅ Reasons to believe
- 80% of analysts rate it a buy (Buy consensus, 5 ratings) — a sign of market conviction.
- Median price target $32, i.e. +53% from the current price ($21).
- The most reliable firm on PRVA, Evercore ISI Group (75% hit rate, 4 scored calls), targets $26 (call made on April 8, 2026, maturing on April 8, 2027) (+25%) in its most recent call, and $30 (call made on November 7, 2025, maturing on November 7, 2026) (+44%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 5 ratings, 1 is neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on PRVA
Median target $32 (+53%) · 5 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Privia Health Group, Inc. now?
We won't decide for you. The facts: 80% of analysts rate it a buy, median target $32 (+53%), and Evercore ISI Group (most reliable on PRVA, 75%) targets $26. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Privia Health Group, Inc.?
Not according to analysts: the median target ($32) is still +53% above the current price ($21) (most reliable on PRVA: Evercore ISI Group, 75%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Privia Health Group, Inc. still worth investing in?
It depends on the gap between the price ($21) and its estimated value: analysts target $32 on median (+53%), with 80% buys (most reliable on PRVA: Evercore ISI Group, 75%). Cross-check with their real reliability on PRVA and the cautions above. Information, not advice.
What's the main risk in buying PRVA?
The consensus is not unanimous: of 5 ratings, 1 is neutral.
→ Go deeper: the full Privia Health Group, Inc. profile (consensus, analyst reliability, price target, performance).